These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25947397)

  • 1. A Pharmacokinetic and Pharmacodynamic Study on Intravenous Cefazedone Sodium in Patients with Community-acquired Pneumonia.
    Gao L; Zhu Y; Lyu Y; Hao FL; Zhang P; Wei MJ
    Chin Med J (Engl); 2015 May; 128(9):1160-4. PubMed ID: 25947397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.
    Öbrink-Hansen K; Hardlei TF; Brock B; Jensen-Fangel S; Kragh Thomsen M; Petersen E; Kreilgaard M
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2398-404. PubMed ID: 25666151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints.
    Stass H; Dalhoff A
    Infection; 2005 Dec; 33 Suppl 2():29-35. PubMed ID: 16518709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia.
    Bhavnani SM; Zhang L; Hammel JP; Rubino CM; Bader JC; Sader HS; Gelone SP; Wicha WW; Ambrose PG
    J Antimicrob Chemother; 2019 Apr; 74(Suppl 3):iii35-iii41. PubMed ID: 30949705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies.
    Owens RC; Shorr AF
    Am J Health Syst Pharm; 2009 Jun; 66(12 Suppl 4):S23-30. PubMed ID: 19502225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion.
    Adembri C; Fallani S; Cassetta MI; Arrigucci S; Ottaviano A; Pecile P; Mazzei T; De Gaudio R; Novelli A
    Int J Antimicrob Agents; 2008 Feb; 31(2):122-9. PubMed ID: 18055183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections.
    Tanigawara Y; Kaku M; Totsuka K; Tsuge H; Saito A
    J Infect Chemother; 2013 Oct; 19(5):858-66. PubMed ID: 23529500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.
    Dong H; Wang X; Dong Y; Lei J; Li H; You H; Wang M; Xing J; Sun J; Zhu H
    Int J Antimicrob Agents; 2011 Oct; 38(4):296-300. PubMed ID: 21741222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic analysis to evaluate ceftaroline fosamil dosing regimens for the treatment of community-acquired bacterial pneumonia and complicated skin and skin-structure infections in patients with normal and impaired renal function.
    Canut A; Isla A; Rodríguez-Gascón A
    Int J Antimicrob Agents; 2015 Apr; 45(4):399-405. PubMed ID: 25700566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic testing of marbofloxacin administered as a single injection for the treatment of bovine respiratory disease.
    Vallé M; Schneider M; Galland D; Giboin H; Woehrlé F
    J Vet Pharmacol Ther; 2012 Dec; 35(6):519-28. PubMed ID: 22126438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.
    Fish DN; Kiser TH
    Pharmacotherapy; 2013 Oct; 33(10):1022-34. PubMed ID: 23744833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A proposal of a pharmacokinetic/pharmacodynamic (PK/PD) index map for selecting an optimal PK/PD index from conventional indices (AUC/MIC, Cmax/MIC, and TAM) for antibiotics.
    Kitamura Y; Yoshida K; Kusama M; Sugiyama Y
    Drug Metab Pharmacokinet; 2014; 29(6):455-62. PubMed ID: 25008846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.
    Lodise TP; Pypstra R; Kahn JB; Murthy BP; Kimko HC; Bush K; Noel GJ; Drusano GL
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2378-87. PubMed ID: 17387149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.
    Zheng Y; Liu SP; Xu BP; Shi ZR; Wang K; Yang JB; Huang X; Tang BH; Chen XK; Shi HY; Zhou Y; Wu YE; Qi H; Jacqz-Aigrain E; Shen AD; Zhao W
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.